Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

• Status: Recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors, GLP-1 and glucagon. Peptides will be intravenously infused, both in isolation, and combination into healthy male participants. Overall, the aim of the study is to further our understanding on the role these endogenous substances play (both in isolation and combination) in haemodynamic regulation.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust
• Treatments: Exenatide; Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• Written informed consent to participate

• Aged 18 to 40

• Male

• Current non-smoker

• BMI >18.0 and <30kg/m2

Exclusion Criteria:

• Female

• Sustained Hypertension (sustained BP >160/100mmHg) or hypotension (systolic BP below 90 mmHg)

• Clinically significant heart disease

• Implanted heart pace-maker or implantable cardioverter defibrillator (ICD)

• Known active malignancy

• Known renal failure (creatinine >140μmol/L)

• Known diabetes mellitus (type 1 or 2)

• Use of vasoactive medications or NSAIDS/aspirin within 24 hours of study visits

• Use of formal anticoagulant therapy such as, but not limited to, heparin, warfarin or rivaroxaban

• Current involvement in the active treatment phase of other research studies, (excluding observations/noninterventional)

• Any other clinical reason which may preclude entry in the opinion of the investigator